Table 4.

Hemoglobin outcomes and red blood cell transfusion requirements at the German center

	Darbepoetin alfa 500 μg Q3W (n=50)	Binocrit® 40,000 IU QW (n=95)
Mean duration of ESA treatment (weeks)	4.28	4.66
Mean Hb at start of ESA treatment (g/dL)	9.92	9.85
Mean Hb at end of EAS treatment (g/dL)	11.93	11.91
Patients requiring red blood cell transfusion during ESA treatment period, n (%)	3 (6.0)	4 (4.2)

Note: Binocrit^® (Sandoz GmbH, Kundl, Austria).

Abbreviations: ESA, erythropoiesis-stimulating agent; Hb, hemoglobin; QW, once weekly; Q3W, once every 3 weeks.